{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-22-000083","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.185300+00:00","generated_at":"2026-06-21T12:58:06.823044+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lifecore Biomedical raises $5.0M via private placement of 627,746 shares at $7.97 each","bullets":["Sold 627,746 shares of common stock at $7.97 each to entities affiliated with Wynnefield Capital, Inc.","Gross proceeds of approximately $5.0 million; transaction closed November 25, 2022.","Purchasers granted piggyback registration rights; offering exempt under Section 4(a)(2) of Securities Act.","Shares issued as unregistered; no specific use of proceeds disclosed in the filing.","Dilution represents about 2.1% of outstanding common stock (29.67M shares pre-offering)."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-22-000083","json":"https://secwatch.observer/filing/0001005286-22-000083.json","markdown":"https://secwatch.observer/filing/0001005286-22-000083.md","text":"https://secwatch.observer/filing/0001005286-22-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/0001005286-22-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/lndc-20221125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:58:06.823044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62d751c2abec7000cb62e90046a3ffe7c914ef38","claim":"LIFECORE BIOMEDICAL, INC. DE entered into Securities Purchase Agreement with entities affiliated with Wynnefield Capital, Inc. valued at approximately $5.0 million (effective 2022-11-25).","evidence_excerpt":"On November 25, 2022, Lifecore Biomedical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with Wynnefield Capital, Inc. (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/0001005286-22-000083-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"entities affiliated with Wynnefield Capital, Inc."},{"label":"Value","value":"approximately $5.0 million"},{"label":"Effective","value":"2022-11-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}